The Clinical Trials Shared Resource (CTSR) facilitates and enhances the efficiency of clinical trial conduct among the many elements of the VICC. It provides critical human resources and benefits including training for inexperienced and experienced investigators in the preparation of protocols for regulatory review and budget development. The major areas of responsibility of the CTSR include support for all regulatory requirements such as IRB submissions and annual reporting, IND submissions and annual reporting, as well as assistance with protocol submissions to the Scientific Review Committee, the GCRC and the NCI; assistance with budget development and contract negotiations and resolution of problems pertaining to resource allocations; data management for all SRC-approved clinical trials; and provision of research nursing support as required by the clinical protocol. In order to meet these goals, CTSR services are grouped into three categories: Shared Resource Services, Data Management Services, and Research Nursing Services. In sum, the primary mission of the CTSR is to assist VICC investigators in developing, activating, and completing scientifically meritorious clinical trials in an efficient, cost-effective, and technically sound manner. Dr. Jeffrey Sosman is the Medical Director of the CTSR. He is assisted by Kelly Willenberg, R. N., the Clinical Director, who is responsible for the day-to-day operations of the CTSR and David Browning, who handles protocol activation and implementation. A multitude of other staff provides support for the widely varying functions of the Clinical Trials Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-09
Application #
6990192
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-28
Project End
2009-08-31
Budget Start
2004-09-28
Budget End
2005-08-31
Support Year
9
Fiscal Year
2004
Total Cost
$232,140
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Bloodworth, Melissa H; Rusznak, Mark; Pfister, Connor C et al. (2018) Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 142:683-687.e12
Saito-Diaz, Kenyi; Benchabane, Hassina; Tiwari, Ajit et al. (2018) APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev Cell 44:566-581.e8
Cardin, Dana B; Thota, Ramya; Goff, Laura W et al. (2018) A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am J Clin Oncol 41:772-776
Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155
Dutter, Brendan F; Ender, Anna; Sulikowski, Gary A et al. (2018) Rhodol-based thallium sensors for cellular imaging of potassium channel activity. Org Biomol Chem 16:5575-5579
Vierra, Nicholas C; Dickerson, Matthew T; Jordan, Kelli L et al. (2018) TALK-1 reduces delta-cell endoplasmic reticulum and cytoplasmic calcium levels limiting somatostatin secretion. Mol Metab 9:84-97
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Lewis Jr, James S; Shelton, Jeremy; Kuhs, Krystle Lang et al. (2018) p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution. Head Neck Pathol 12:440-447
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858

Showing the most recent 10 out of 2462 publications